Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study.

IMPORTANCE Data from an autosomal dominant Alzheimer disease (ADAD) kindred were used to track the longitudinal trajectory of cognitive decline associated with preclinical ADAD and explore factors that may modify the rate of cognitive decline. OBJECTIVES To evaluate the onset and rate of cognitive decline during preclinical ADAD and the effect of socioeconomic, vascular, and genetic factors on the cognitive decline. DESIGN, SETTING, AND PARTICIPANTS We performed a retrospective cohort study from January 1, 1995, through June 31, 2012, of individuals from Antioquia, Colombia, who tested positive for the ADAD-associated PSEN1 E280A mutation. Data analysis was performed from August 20, 2014, through November 30, 2015. A mixed-effects model was used to estimate annual rates of change in cognitive test scores and to mark the onset of cognitive decline. MAIN OUTCOMES AND MEASURES Memory, language, praxis, and total scores from the Consortium to Establish a Registry for Alzheimer Disease test battery. Chronologic age was used as a time scale in the models. We explore the effects of sex; educational level; socioeconomic status; residence area; occupation type; marital status; history of hypertension, diabetes mellitus, and dyslipidemia; tobacco and alcohol use; and APOE ε4 on the rates of cognitive decline. RESULTS A total of 493 carriers met the inclusion criteria and were analyzed. A total of 256 carriers had 2 or more assessments. At the time of the initial assessment, participants had a mean (SD) age of 33.4 (11.7) years and a mean (SD) educational level of 7.2 (4.2) years. They were predominantly female (270 [54.8%]), married (293 [59.4%]), and of low socioeconomic status (322 [65.3%]). Word list recall scores provided the earliest indicator of preclinical cognitive decline at 32 years of age, 12 and 17 years before the kindred's respective median ages at mild cognitive impairment and dementia onset. After the change point, carriers had a statistically significant cognitive decline with a loss of 0.24 (95% CI, -0.26 to -0.22) points per year for the word list recall test and 2.13 (95% CI, -2.29 to -1.96) points per year for total scores. Carriers with high educational levels had an increase of approximately 36% in the rate of cognitive decline after the change point when compared with those with low educational levels (-2.89 vs -2.13 points per year, respectively). Onset of cognitive decline was delayed by 3 years in individuals with higher educational levels compared with those with lower educational levels. Those with higher educational level, middle/high socioeconomic status, history of diabetes and hypertension, and tobacco and alcohol use had a steeper cognitive decline after onset. CONCLUSIONS AND RELEVANCE Preclinical cognitive decline was evident in PSEN1 E280A mutation carriers 12 years before the onset of clinical impairment. Educational level may be a protective factor against the onset of cognitive impairment.

[1]  Ardo van den Hout,et al.  Change point models for cognitive tests using semi-parametric maximum likelihood , 2013, Comput. Stat. Data Anal..

[2]  P. Diggle,et al.  Analysis of Longitudinal Data , 2003 .

[3]  A. Myers,et al.  E280A PS‐1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles , 1997, Human mutation.

[4]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[5]  C B Hall,et al.  A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. , 2000, Statistics in medicine.

[6]  S. Leurgans,et al.  A Random Change Point Model for Cognitive Decline in Alzheimer’s Disease and Mild Cognitive Impairment , 2012, Neuroepidemiology.

[7]  F. Lopera,et al.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study , 2011, The Lancet Neurology.

[8]  F. Panza,et al.  Vascular risk factors, alcohol intake, and cognitive decline , 2008, The journal of nutrition, health & aging.

[9]  A. Fagan,et al.  Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. , 2015, JAMA neurology.

[10]  E. L. Mortensen,et al.  Socio-economic position early in life, cognitive development and cognitive change from young adulthood to middle age. , 2013, European journal of public health.

[11]  F. Lopera,et al.  Análisis de las intrusiones en una prueba de memoria como posible marcador preclínico de enfermedad de Alzheimer en portadores de la mutación E280A de la presenilina-1 , 2008 .

[12]  Eric M Reiman,et al.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study , 2012, The Lancet Neurology.

[13]  W. Jagust,et al.  The Role of APOE ∊4 in Modulating Effects of Other Risk Factors for Cognitive Decline in Elderly Persons , 1999 .

[14]  R. B. Lipton,et al.  Education delays accelerated decline on a memory test in persons who develop dementia , 2007, Neurology.

[15]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[16]  Kenneth S. Kosik,et al.  Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred , 2003 .

[17]  M F Weiner,et al.  A total score for the CERAD neuropsychological battery , 2005, Neurology.

[18]  Francisco Lopera,et al.  Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease , 2010, Annals of neurology.

[19]  T. Salthouse.  When does age-related cognitive decline begin? , 2009, Neurobiology of Aging.

[20]  Eric M Reiman,et al.  Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[22]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[23]  Reisa A. Sperling,et al.  Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease , 2014, Science Translational Medicine.

[24]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[25]  Lynn Kuo,et al.  Bayesian and profile likelihood change point methods for modeling cognitive function over time , 2003, Comput. Stat. Data Anal..

[26]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[27]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[28]  A. Álvarez,et al.  Spectral Analysis of EEG in Familial Alzheimer's Disease with E280A Presenilin-1 Mutation Gene , 2014, International journal of Alzheimer's disease.

[29]  Jessica C. Payne-Murphy,et al.  Trajectory of mild cognitive impairment onset , 2008, Journal of the International Neuropsychological Society.

[30]  H. Amièva,et al.  Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline. , 2014, Brain : a journal of neurology.